最新の財務諸表(Form-10K)によると、Aspira Women's Health Incの総資産は$5で、純損失は$-13です。
AWHLの主要な財務比率は何ですか?
Aspira Women's Health Incの流動比率は0.62、純利益率は-144.44、1株当たり売上高は$0.63です。
Aspira Women's Health Incの収益はセグメントまたは地域別にどのように分けられていますか?
Aspira Women's Health Inc の最大収益セグメントは Bio-analytic and Diagnostic Services で、最新の利益発表における収益は 9,154,000 です。地域別に見ると、United States が Aspira Women's Health Inc の主要市場であり、収益は 9,154,000 です。
Aspira Women's Health Incは収益を上げていますか?
いいえ、最新の財務諸表によると、Aspira Women's Health Incの純損失は$-13です。
Aspira Women's Health Incに負債はありますか?
はい、Aspira Women's Health Incの負債は8です。
Aspira Women's Health Incの発行済株式数は何株ですか?
Aspira Women's Health Incの総発行済株式数は17.4株です。
主要データ
前終値
$0.34
始値
$0.32
当日レンジ
$0.281 - $0.335
52週レンジ
$0.02 - $0.71
取引高
10.0K
平均取引高
48.8K
配当利回り
--
1株当たり利益(TTM)
-0.99
時価総額
$16.6M
AWHLとは何ですか?
Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. The company is headquartered in Austin, Texas and currently employs 66 full-time employees. The company went IPO on 2000-09-29. The firm's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus is a reflex process of two tests, Ova1 and Overa, to assess the risk of ovarian malignancy in women with an adnexal mass planned for surgery. Its product pipelines are OVAinform and ENDOinform. OVAinform is a test that combines serum proteins, clinical data (metadata), and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass. ENDOinform is a test program that combines serum proteins, clinical data (metadata), and miRNA for the identification of endometriosis.